{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T09:27:10Z","timestamp":1794994030189,"version":"4.9.1"},"reference-count":34,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,8,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Allogeneic hematopoietic cell transplantation in multiple myeloma is limited by prior reports of high treatment-related mortality. We analyzed outcomes after allogeneic hematopoietic cell transplantation for multiple myeloma in 1207 recipients in 3 cohorts based on the year of transplantation: 1989-1994 (n = 343), 1995-2000 (n = 376), and 2001-2005 (n = 488). The most recent cohort was significantly older (53% &gt; 50 years) and had more recipients after prior autotransplantation. Use of unrelated donors, reduced-intensity conditioning and the blood cell grafts increased over time. Rates of acute graft-versus-host (GVHD) were similar, but chronic GVHD rates were highest in the most recent cohort. Overall survival (OS) at 1-year increased over time, reflecting a decrease in treatment-related mortality, but 5-year relapse rates increased from 39% (95% confidence interval [CI], 33%-44%) in 1989-1994 to 58% (95% CI, 51%-64%; P &lt; .001) in the 2001-2005 cohort. Projected 5-year progression-free survival and OS are 14% (95% CI, 9%-20%) and 29% (95% CI, 23%-35%), respectively, in the latest cohort. Increasing age, longer interval from diagnosis to transplantation, and unrelated donor grafts adversely affected OS in multivariate analysis. Survival at 5 years for subjects with none, 1, 2, or 3 of these risk factors were 41% (range, 36%-47%), 32% (range, 27%-37%), 25% (range, 19%-31%), and 3% (range, 0%-11%), respectively (P &lt; .0001).<\/jats:p>","DOI":"10.1182\/blood-2011-02-337329","type":"journal-article","created":{"date-parts":[[2011,6,21]],"date-time":"2011-06-21T03:49:41Z","timestamp":1308628181000},"page":"1979-1988","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":69,"title":["Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis"],"prefix":"10.1182","volume":"118","author":[{"given":"Shaji","family":"Kumar","sequence":"first","affiliation":[{"name":"Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Jie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peigang","family":"Li","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo A.","family":"Milone","sequence":"additional","affiliation":[{"name":"Fundaleu, Buenos Aires, Argentina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Emory University Hospital, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Krishnan","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, City of Hope National Medical Center, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Maiolino","sequence":"additional","affiliation":[{"name":"Hospital Universitario Clementino Fraga Filho, Rio de Janeiro, Brazil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baldeep","family":"Wirk","sequence":"additional","affiliation":[{"name":"Shands HealthCare and University of Florida, Gainesville, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Weiss","sequence":"additional","affiliation":[{"name":"Walter Reed Army Medical Center, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar O.","family":"Freytes","sequence":"additional","affiliation":[{"name":"UTHSC Veterans Health Care System, San Antonio, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan T.","family":"Vogl","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Vesole","sequence":"additional","affiliation":[{"name":"Hackensack University Medical Center, Hackensack, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillard M.","family":"Lazarus","sequence":"additional","affiliation":[{"name":"University Hospitals Case Medical Center, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth R.","family":"Meehan","sequence":"additional","affiliation":[{"name":"Dartmouth Hitchcock Medical Center, Lebanon, NH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"West Virginia University Hospitals Inc, Morgantown, WV;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lill","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Medical Center, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie S.","family":"Callander","sequence":"additional","affiliation":[{"name":"University of Wisconsin Hospital and Clinics, Madison, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navneet S.","family":"Majhail","sequence":"additional","affiliation":[{"name":"University of Minnesota Medical Center, Fairview, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter H.","family":"Wiernik","sequence":"additional","affiliation":[{"name":"Continuum Cancer Center at St Luke's-Roosevelt Medical Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajneesh","family":"Nath","sequence":"additional","affiliation":[{"name":"UMass Memorial Medical Center, Worcester, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rammurti T.","family":"Kamble","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine Center for Cell and Gene Therapy, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[{"name":"Barnes Jewish Hospital, St Louis, MO; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[{"name":"Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[{"name":"Celgene Corporation, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran N.","family":"Hari","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2019111807580346600_B1","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/mcp.2009.0603","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines.","volume":"84","author":"Kumar","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"2019111807580346600_B2","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2009.127","article-title":"International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).","volume":"23","author":"Giralt","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"2019111807580346600_B3","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/leu.2008.396","article-title":"Role of autologous and allogeneic stem cell transplantation in myeloma.","volume":"23","author":"Bensinger","year":"2009","journal-title":"Leukemia"},{"issue":"12","key":"2019111807580346600_B4","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bmt.1704968","article-title":"Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma.","volume":"35","author":"Arora","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2019111807580346600_B5","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1182\/blood.V88.12.4711.bloodjournal88124711","article-title":"Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation.","volume":"88","author":"Bjorkstrand","year":"1996","journal-title":"Blood"},{"issue":"12","key":"2019111807580346600_B6","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/sj.bmt.1704289","article-title":"Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.","volume":"32","author":"Alyea","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2019111807580346600_B7","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.bbmt.2007.04.006","article-title":"Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.","volume":"13","author":"Kuruvilla","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111807580346600_B8","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","article-title":"Graft-versus-myeloma effect: proof of principle.","volume":"87","author":"Tricot","year":"1996","journal-title":"Blood"},{"issue":"11","key":"2019111807580346600_B9","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1200\/JCO.2000.18.11.2273","article-title":"Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma.","volume":"18","author":"Martinelli","year":"2000","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111807580346600_B10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1182\/blood.V96.1.355","article-title":"Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma.","volume":"96","author":"Cavo","year":"2000","journal-title":"Blood"},{"issue":"5","key":"2019111807580346600_B11","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1182\/blood-2003-01-0189","article-title":"Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.","volume":"102","author":"Corradini","year":"2003","journal-title":"Blood"},{"issue":"1","key":"2019111807580346600_B12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1365-2141.2001.02726.x","article-title":"Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres.","volume":"113","author":"Gahrton","year":"2001","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111807580346600_B13","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1182\/blood.V90.12.4705","article-title":"Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease.","volume":"90","author":"Storek","year":"1997","journal-title":"Blood"},{"issue":"21","key":"2019111807580346600_B14","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.41.41","article-title":"Tandem Autologous hematopoietic stem cell transplants (AuHCT) with or without maintenance therapy (auto-auto) versus single AuHCT followed by HLA matched sibling non-myeloablative allogeneic HCT (auto-allo) for patients with standard risk (SR) multiple myeloma (MM): results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 trial [abstract].","volume":"116","author":"Krishnan","year":"2010","journal-title":"Blood"},{"issue":"21","key":"2019111807580346600_B15","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.526.526","article-title":"Tandem autologous stem cell transplants (auto-auto) with or without maintenance therapy versus single autologous transplant followed by HLA-matched sibling non-myeloablative allogeneic stem cell transplant (auto-auto) for patients (pts) with high risk (HR) multiple myeloma (MM). results from the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0102 Trial [abstract].","volume":"116","author":"Stadtmauer","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2019111807580346600_B16","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"issue":"11","key":"2019111807580346600_B17","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A comparison of allografting with autografting for newly diagnosed myeloma.","volume":"356","author":"Bruno","year":"2007","journal-title":"N Engl J Med"},{"issue":"29","key":"2019111807580346600_B18","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1200\/JCO.2010.29.7929","article-title":"International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma.","volume":"28","author":"Lokhorst","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111807580346600_B19","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.52.52","article-title":"Tandem autologous(ASCT)\/allogeneic reduced intensity conditioning transplantation (RIC) with identical sibling donor versus ASCT in previously untreated multiple myeloma (MM): long term follow up of a prospective controlled trial by the EBMT [abstract].","volume":"114","author":"Gahrton","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2019111807580346600_B20","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies.","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2019111807580346600_B21","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with multiple myeloma.","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"issue":"9","key":"2019111807580346600_B22","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.bmt.1703253","article-title":"Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect.","volume":"28","author":"Le Blanc","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2019111807580346600_B23","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","article-title":"A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma.","volume":"112","author":"Rosinol","year":"2008","journal-title":"Blood"},{"issue":"18","key":"2019111807580346600_B24","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1056\/NEJM199110313251802","article-title":"Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation.","volume":"325","author":"Gahrton","year":"1991","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111807580346600_B25","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/sj.bmt.1705161","article-title":"Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma.","volume":"36","author":"Gerull","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2019111807580346600_B26","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.bbmt.2004.06.002","article-title":"Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan\/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.","volume":"10","author":"Kroger","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2019111807580346600_B27","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1182\/blood-2003-12-4435","article-title":"Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation.","volume":"103","author":"Kroger","year":"2004","journal-title":"Blood"},{"issue":"6","key":"2019111807580346600_B28","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/leu.2008.88","article-title":"Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.","volume":"22","author":"Schilling","year":"2008","journal-title":"Leukemia"},{"issue":"11","key":"2019111807580346600_B29","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma.","volume":"101","author":"Fonseca","year":"2003","journal-title":"Blood"},{"issue":"11","key":"2019111807580346600_B30","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3324\/haematol.11353","article-title":"Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma.","volume":"92","author":"Gahrton","year":"2007","journal-title":"Haematologica"},{"issue":"11","key":"2019111807580346600_B31","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2004-06-2387","article-title":"Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.","volume":"105","author":"Crawley","year":"2005","journal-title":"Blood"},{"issue":"9","key":"2019111807580346600_B32","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1038\/sj.leu.2404775","article-title":"Mini-Midi-Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation.","volume":"21","author":"Kroger","year":"2007","journal-title":"Leukemia"},{"issue":"6","key":"2019111807580346600_B33","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.bmt.1703652","article-title":"Fludarabine\/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.","volume":"30","author":"Giralt","year":"2002","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2019111807580346600_B34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.bmt.1701280","article-title":"High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma.","volume":"22","author":"Cavo","year":"1998","journal-title":"Bone Marrow Transplant"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/7\/1979\/1347643\/zh803311001979.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/7\/1979\/1347643\/zh803311001979.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T13:13:01Z","timestamp":1574082781000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/7\/1979\/29691\/Trends-in-allogeneic-stem-cell-transplantation-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,18]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,8,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-02-337329","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,18]]}}}